[ RECIPIENT ENTITY RECORD ]

Aiolos Bio

VERIFIED NODE ID: 001382 · aiolos-bio
R TARGET NODE — CAPITAL RECIPIENT
Aiolos Bio
Company United States
Recipient Type
Company
Primary Jurisdiction
United States
Registration Status
ACTIVE
Entity Intelligence [ R ]
Legal Name Aiolos Bio
Entity Type Company
Jurisdiction United States
Recipient Intelligence Summary

Aiolos Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory and inflammatory diseases. The firm’s lead program targets asthma through advanced antibody technology. It is a notable recipient of institutional healthcare capital through its recent acquisition by a global biopharma major.

Capital Influx Log (Transactions)
Date Type Amount
19 May 2026 EQUITY $1.4B